The Pharmaceutical Managers Institute

The PMI is a professional membership organisation dedicated to the continuous learning, development and support of those working in management within the pharmaceutical industry. Our membership is diverse, covering Commercial, Marketing, Market Access, Product Management and Regulatory roles; representating over 80 pharmaceutical organisations.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA TECH

BAYER AND MAMMOTH BIOSCIENCES TO COLLABORATE ON NOVEL GENE EDITING TECHNOLOGY

Bayer and Mammoth Biosciences | January 10, 2022

news image

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies. Mammoth Biosciences’ groundbreaking gene-editing technology is a key enabling technology, as well as a stand-alone therapeutic modality. It will significantly enhance Bayer’s efforts to develop tra...

Read More

GRIFOLS TO ACQUIRE MONTREAL-BASED PLASMA FRACTIONATION FACILITY AND TWO PURIFICATION FACILITIES FOR US$460 MILLION

Grifols, Green Cross Corporation | July 21, 2020

news image

Grifols, a global healthcare company and one of world's top producers of plasma-derived medicines, today announced it has executed purchase arrangements with the South Korean-based GC Pharma (Group) whereby Grifols will acquire the Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.-based plasma collection centers for a total amount of US$460 million. The transaction is part of Grifols' sustainable global growth strategy to expa...

Read More

BUSINESS INSIGHTS

CYCLENIUM PHARMA AND VUJA DE SCIENCES ANNOUNCE ONCOLOGY DRUG DISCOVERY COLLABORATION

Cyclenium Pharma | January 06, 2022

news image

Cyclenium Pharma, Inc. an emerging pharmaceutical company specializing in the discovery and development of novel therapeutic agents based on their proprietary macrocyclic chemistry, and Vuja De Sciences, Inc. a biotechnology startup dedicated to discovering therapies that target the unique vulnerability of undetected disseminated tumor cells before they can cause deadly metastatic cancer recurrence, have announced today the signing of a drug discovery collaboration agreement. The companies will ...

Read More

BUSINESS INSIGHTS

SIGNET HEALTHCARE PARTNERS COMPLETES GROWTH EQUITY INVESTMENT IN JUNO PHARMACEUTICALS CORP

Juno Pharmaceuticals | February 25, 2022

news image

Juno Pharmaceuticals Corp a Canadian specialty generics pharmaceuticals company, announced that it has received a strategic growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare growth equity firm. Juno intends to use these proceeds to expand its complex and high-value generic and biosimilar portfolio and to accelerate growth. “We are very pleased with the opportunity to partner with the Juno management te...

Read More
news image

PHARMA TECH

BAYER AND MAMMOTH BIOSCIENCES TO COLLABORATE ON NOVEL GENE EDITING TECHNOLOGY

Bayer and Mammoth Biosciences | January 10, 2022

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies. Mammoth Biosciences’ groundbreaking gene-editing technology is a key enabling technology, as well as a stand-alone therapeutic modality. It will significantly enhance Bayer’s efforts to develop tra...

Read More
news image

GRIFOLS TO ACQUIRE MONTREAL-BASED PLASMA FRACTIONATION FACILITY AND TWO PURIFICATION FACILITIES FOR US$460 MILLION

Grifols, Green Cross Corporation | July 21, 2020

Grifols, a global healthcare company and one of world's top producers of plasma-derived medicines, today announced it has executed purchase arrangements with the South Korean-based GC Pharma (Group) whereby Grifols will acquire the Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.-based plasma collection centers for a total amount of US$460 million. The transaction is part of Grifols' sustainable global growth strategy to expa...

Read More
news image

BUSINESS INSIGHTS

CYCLENIUM PHARMA AND VUJA DE SCIENCES ANNOUNCE ONCOLOGY DRUG DISCOVERY COLLABORATION

Cyclenium Pharma | January 06, 2022

Cyclenium Pharma, Inc. an emerging pharmaceutical company specializing in the discovery and development of novel therapeutic agents based on their proprietary macrocyclic chemistry, and Vuja De Sciences, Inc. a biotechnology startup dedicated to discovering therapies that target the unique vulnerability of undetected disseminated tumor cells before they can cause deadly metastatic cancer recurrence, have announced today the signing of a drug discovery collaboration agreement. The companies will ...

Read More
news image

BUSINESS INSIGHTS

SIGNET HEALTHCARE PARTNERS COMPLETES GROWTH EQUITY INVESTMENT IN JUNO PHARMACEUTICALS CORP

Juno Pharmaceuticals | February 25, 2022

Juno Pharmaceuticals Corp a Canadian specialty generics pharmaceuticals company, announced that it has received a strategic growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare growth equity firm. Juno intends to use these proceeds to expand its complex and high-value generic and biosimilar portfolio and to accelerate growth. “We are very pleased with the opportunity to partner with the Juno management te...

Read More